Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jan;159(1):e7-e11.
doi: 10.1016/j.chest.2020.09.077. Epub 2020 Sep 12.

Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019

Affiliations
Case Reports

Etoposide as Salvage Therapy for Cytokine Storm Due to Coronavirus Disease 2019

Maulin Patel et al. Chest. 2021 Jan.

Abstract

Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality because of a lack of effective therapies. Therapeutic strategies under investigation target the overactive cytokine response with anti-cytokine or immunomodulators therapies. We present a unique case of severe cytokine storm resistant to multiple anti-cytokine therapies, but eventually responsive to etoposide. Thus, etoposide may have a role as salvage therapy in treatment of cytokine storm in COVID-19. To our knowledge, this is the first reported case of use of etoposide in COVID-19.

Keywords: COVID-19; etoposide.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT angiography of the thorax. A, Arrow shows right lower lobe pulmonary embolism. B, Multifocal peripheral ground-glass opacities.
Figure 2
Figure 2
Trends of laboratory and clinical markers.
Figure 3
Figure 3
Chest radiograph progression for patient 1. A, Day 1, showing diffuse bilateral interstitial and airspace opacities throughout both lungs with a basilar predominance. B, Day 8, with improved interstitial/airspace opacities. C, Day 14, increased infiltrate on right lung base. D, Day 20, worsening patchy opacities with basilar predominance. E, Day 26, improvement in opacities 5 days after receiving etoposide. F, Day 29, continued improvement in opacities after etoposide.

Comment in

  • Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.
    Delgado-López PD, Buzón-Martín L, Montero-Baladia M, Astigarraga I. Delgado-López PD, et al. Chest. 2021 Apr;159(4):1678-1679. doi: 10.1016/j.chest.2020.10.090. Epub 2021 Apr 6. Chest. 2021. PMID: 34021998 Free PMC article. No abstract available.
  • Response.
    Patel M, Dominguez E, Sacher D, Desai P, Chandar A, Bromberg M, Caricchio R, Criner GJ. Patel M, et al. Chest. 2021 Apr;159(4):1679. doi: 10.1016/j.chest.2020.11.035. Epub 2021 Apr 6. Chest. 2021. PMID: 34021999 Free PMC article. No abstract available.

References

    1. COVID-19 Map—Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html
    1. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034. - PMC - PubMed
    1. Tveiten H., Aukrust P., Lehne G., Rodriguez J.R., Skjønsberg O.H. Haemophagocytic lymphohistiocytosis in COVID-19 cases? Tidsskr Den Nor legeforening. 2020 doi: 10.4045/TIDSSKR.20.0240. [Published online ahead of print March 23, 2020] - DOI - PubMed
    1. Li X., Geng M., Peng Y., Meng L., Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. - PMC - PubMed
    1. Huang C., Wang Y., Li X. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. - PMC - PubMed

Publication types